The global Lyophilized
Drugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics,
Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s (Nonsteroidal
anti-inflammatory drugs), and Others), by Indication (Infectious Disease,
Autoimmune Disease, Gastrointestinal Disease, Cancer, and Others), by Packaging
Type (Vial, Injection, and Cartridge), and by region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be
valued at US$ 322.9 Billion in 2018, and is projected to exhibit a CAGR of
7.1%, during the forecast period (2018-2026), as highlighted in a new report
published by Coherent Market Insights.
Increasing number of product launches
for lyophilized drugs is contributing to growth of the global lyophilized drugs
market. For instance, in July 2015, Sandoz AG launched a generic version of
ANGIOMAX (bivalirudin) for injection in the U.S market after completing a
supply and distribution agreement with The Medicines Company. The drug is used
as an anticoagulant agent for treating patients with unstable angina,
undergoing percutaneous transluminal coronary angioplasty (PTCA), and
percutaneous coronary intervention (PCI). Increasing focus of manufacturers on
the development of innovative lyophilization technologies and services, in
order to manufacture lyophilized drug with utmost quality and capacity, is
contributing to lyophilized drugs market growth.
For instance, in May 2015, Symbiosis
Pharmaceutical Services, Sterile manufacturing CMO, announced to offer a new
bulk lyophilization (freeze drying) service, in order to meet utmost quality in
the manufacturing of bulk intermediates and APIs by lyophilization. Thus,
development of such novel service platforms isw creating opportunity for
manufacturers to expand in lyophilized drugs, thus, aiding in growth of the
market in the near future.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2930
Browse 35 Market Data Tables and
38 Figures spread through 208 Pages and in-depth TOC on "Global Lyophilized
Drugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton
Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, and Others), by Indication
(Infectious Disease, Autoimmune Disease, Gastrointestinal Disease, Cancer, and
Others), by Packaging Type (Vial, Injection, and Cartridge), and by region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Global Forecast to 2026".
Increasing regulatory approval
for lyophilized drug is contributing to lyophilized drugs market growth. For
instance, in September 2018, Novartis Pharmaceuticals Corporation received the
U.S. Food and Drug Administration approval for its Xolair (omalizumab)
prefilled syringe formulation, for the treatment of moderate to severe
persistent allergic asthma and chronic idiopathic urticarial. The drug is available
in a 150 mg single-dose vial with lyophilized, sterile powder for
reconstitution. Moreover, increasing investments and facility expansion is
expected to show significant growth for the global lyophilized drugs market.
In August 2016, Dalton Pharma
Services completed an investment of US$ 5 million for expansion of its sterile
filling and active pharmaceutical ingredient (API) manufacturing facility at
its current good manufacturing practices (cGMP) facility in Toronto, Canada.
This expansion project added three new sterile processing facilities, an API
manufacturing facility, and a semi-automated powder filling line with scale-up
of lyophilization capacity.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/lyophilized-drugs-market-2930
Key Takeaways of the Global
Lyophilized Drugs Market:
The global lyophilized drugs
market is expected to expand at a CAGR of 7.1% during the forecast period
(2018–2026), owing to increasing initiatives by key players to develop
prominent technologies for patient identification
Increasing acquisitions by key
players for expanding lyophilized drugs business is expected to drive the
global lyophilized drugs market growth. For instance, in November 2018,
Argonaut Manufacturing Services, a contract development and manufacturing
organization (CDMO) serving molecular diagnostic and biopharmaceutical
companies, acquired LyoGen LLC. With this acquisition, Argonaut expanded its
reagent lyophilization capabilities from process development through production
scale deployment.
Major players operating in the
global lyophilized drugs market include Sanofi S.A, Merck & Co., Inc.,
Fresenius Kabi USA, LLC., Ciron Drugs & Pharmaceuticals Pvt Ltd.,
GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC,
Otsuka Holdings Co., Ltd. (Otsuka
Pharmaceutical Co., Ltd.), and BTG Plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2930
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment